Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 4/20 | 0.66 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.50 |
| ▸ | MMP14 | P50281 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MMP1 | P03956 | 3/20 | 0.45 |
| ▸ | MMP13 | P45452 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7428128 | 0.94 | SOS1 (0.59) | SOS1FFAR1FFAR4MMP2MMP9 | |
| SCHEMBL9720036 | 0.89 | HTT (0.58) | SOS1HTTALDH1A1MEN1KMT2A | |
| SCHEMBL433497 | 0.89 | HTT (0.58) | SOS1HTTALDH1A1MEN1KMT2A | |
| SCHEMBL17242 | 0.87 | ALDH1A1 (0.55) | SOS1MMP2MMP9ALDH1A1MMP1 | |
| SCHEMBL38661446 | 0.87 | ALDH1A1 (0.55) | SOS1MMP2MMP9ALDH1A1MMP1 | |
| Ammonia Solution, Strong SCHEMBL28862290 | 0.84 | ALDH1A1 (0.52) | SOS1MMP2MMP9ALDH1A1MMP1 | |
| SCHEMBL26131622 | 0.83 | HSPB1 (0.56) | SOS1FFAR1FFAR4MMP2HSPB1 | |
| SCHEMBL9779005 | 0.83 | SOS1 (0.70) | SOS1FFAR1FFAR4MMP2MMP9 | |
| SCHEMBL14138146 | 0.83 | SOS1 (0.70) | SOS1FFAR1FFAR4MMP2MMP9 | |
| SCHEMBL11519866 | 0.83 | SOS1 (0.70) | SOS1FFAR1FFAR4MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11322704-A | — | — | None | — | — | JP | disclosed |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2024-05-30 | — | — | US | disclosed |
| EP-4288412-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | Rappta Therapeutics Oy (FI) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022167866-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2022-08-11 | — | — | WO | disclosed |
| EP-3285583-B1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2021-03-17 | — | — | EP | disclosed |
| US-20190322676-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARM INC (US) | 2019-10-24 | — | — | US | disclosed |
| WO-2018118838-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| EP-3285583-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | The Regents of The University of Michigan (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9884841-B2 | Small molecule inhibitors of Mcl-1 and uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-02-06 | — | — | US | disclosed |
| WO-2016172218-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-10-27 | — | — | WO | disclosed |
| EP-0949244-A2 | Process for preparing hydroxamic acids | Pfizer Products Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0949245-A1 | Process for alkylating hindered sulfonamides | Pfizer Products Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0949246-A1 | Process for preparing phenoxyphenylsulfonyl halides | Pfizer Products Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1999042443-A1 | SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES | NOVARTIS AG (CH) | 1999-08-26 | — | — | WO | disclosed |
| WO-1998050348-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES | AGOURON PHARMACEUTICALS, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
| EP-0874830-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES, AND METHODS AND INTERMEDIATES USEFUL FOR THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1998043963-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES | AGOURON PHARMACEUTICALS, INC. (US) | 1998-10-08 | — | — | WO | disclosed |
| WO-1998034915-A1 | N-HYDROXY-BETA-SULFONYL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASES | PFIZER INC. (US) | 1998-08-13 | — | — | WO | disclosed |
| WO-1998033768-A1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-08-06 | — | — | WO | disclosed |
| WO-1997020824-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES, AND METHODS AND INTERMEDIATES USEFUL FOR THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | PPM1A, PPP2CA, PPP3CA | SOS1 3547/4885FFAR1 1578/4885FFAR4 2003/4885 |
| US-20190322676-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | UGCG, MAN2B1, GBA1 | SOS1 3714/4885FFAR1 2240/4885FFAR4 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.